According to the most recent report by Emergent Research, the worldwide biologics market is anticipated to reach USD 567.96 billion in 2028 at a consistent revenue CAGR of 8.4% throughout the forecast period. Rising demand for monoclonal antibodies, recombinant hormones/proteins, gene- and cellular-based biologics, vaccines, and molecular therapy, among other things, are some important factors contributing to the steady growth of the market’s revenue. These diseases include cancer, infectious diseases, immunological diseases, cardiovascular diseases, and hematological diseases, among others. Ankylosing spondylitis, rheumatoid arthritis, and psoriatic arthritis are just a few of the autoimmune disorders that biologics are increasingly being used to treat. This is propelling the worldwide biologics market’s revenue growth. As a result of biologics’ ability to disrupt inflammation, there is a decrease in joint pain
One important element causing consistent market revenue growth is the rising demand for and increased adoption of innovative biologics medications and therapies for the treatment of medical conditions around the world. Antibody-Medicine Conjugate (ADC), a potent medication used in the treatment of sickness, is one such new drug. In the treatment of cancer, ADC delivers medications with extremely high specificity to the disease/target cells, maximizing effectiveness and minimizing systemic exposure as well as associated side effect concerns. The use of ADC can be used to affect a variety of biological processes depending on the payload connected to the antibody.
Additionally, the burden of chronic diseases, which is rising quickly worldwide, is boosting market expansion. The World Health Organization (WHO) has issued statistics showing that the burden of chronic diseases is expected to rise by 57.0% between 2001 and 2020. The burden of chronic diseases in developing nations, which accounts for 60.0% of the worldwide burden, is anticipated to be significantly increased.
Mylan and Biocon Biologics Ltd. announced in September 2020 that Semglee, a biosimilar, would be available in the US. This biosimilar, which comes in pre-filled pens and vials, is used to lower blood pressure in people with type 2 diabetes in adults as well as type 1 diabetes in children.
Mylan and Biocon Biologics Ltd. announced in September 2020 that Semglee, a biosimilar, would be available in the US. This biosimilar, which comes in pre-filled pens and vials, is used to lower blood pressure in people with type 2 diabetes in adults as well as type 1 diabetes in children.
The vaccines segment revenue is anticipated to grow at a considerably faster rate throughout the projection period among the product type segments. A vaccine works by assisting the immune system in recognizing and combating bacteria or viruses that are pathogens. Due to the effectiveness of vaccinations in lowering communicable diseases that may be prevented, fewer people are currently affected by the distressing symptoms of diseases like measles and pertussis, among others. To stop the spread of COVID-19 and the subsequent deaths brought on by the disease, vaccination demand is currently skyrocketing around the globe.
The cancer application segment had the highest revenue share among the application segments in 2020. Biologics help the immune system swiftly identify cancer cells in the body, fight the diseased cells, turn on and off the signals from cancerous cells, and help immune system cells avoid the cancerous cells.
Due to superior healthcare infrastructure, increased investments in the research of biologics, and better reimbursement conditions in some countries in the area, the market in the Asia Pacific is anticipated to grow at the quickest rate in terms of revenue throughout the forecast period.
Some major companies operating in the global market include Novo Nordisk A/S, Pfizer Inc., Amgen, Sanofi, Samsung BioLogics, Merck & Co. Inc., Celltrion, AbbVie Inc., Johnson & Johnson Services Inc., Eli Lilly & Company, F Hoffman La Roche, Addgene, Novartis AG, and GlaxoSmithKline.
Emergen Research has segmented the global biologics based on source, product type, application, and region:
Source Outlook (Revenue, USD Billion; 2018-2028)
- Microbial
- Mammalian
- Others
Product Type Outlook (Revenue, USD Billion; 2018-2028)
- Monoclonal Antibodies
- Vaccines
- Recombinant Hormones/Proteins
- Cellular-Based Biologics
- Gene-Based Biologics
- Others
Application Outlook (Revenue, USD Billion; 2018-2028)
- Cancer
- Infectious Diseases
- Immunological Diseases
- Cardiovascular Diseases
- Hematological Disorders
- Others
Regional Outlook (Revenue, USD Billion; 2018–2028)
- North America
- the U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- the U.K.
- Italy
- Spain
- BENELUX
- Rest of Europe
- the Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of MEA
To get leading market solutions, -Visit the Link